AllAnalyst Report
logoMorningstarFebruary 13, 2024

Catalent, Inc.: Catalent Earnings: COVID-19 Product Sales Fall; Novo Holdings Acquisition to Expand Wegovy Capacity

Symbols
CTLT
Sector(s)
Healthcare
Rating
Current Price
$55.92
Fair Value
Economic Moat
Stewardship
Summary

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade